Complete withdrawal of hepatitis B virus prophylaxis after liver transplantation in a recipient at high risk of recurrence.

Tian Shen, Yufu Ye, Lei Geng, Shusen Zheng

Abstract readCase Reports

In one paragraph

Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it

0cells of the map it votes in

3citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

A model integrating donor gene polymorphisms predicts fibrosis after liver transplantation.Aging · 2020
Article
Prevention of HBV Recurrence after Liver Transplant: A Review.Journal of clinical and translational hepatology · 2020
Review
Managing HBV and HCV Infection Pre- and Post-liver Transplant.Journal of clinical and experimental hepatology
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Tian ShenDepartment of Surgery, Division of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University Zhejiang, China.

Yufu YeDepartment of Surgery, Division of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University Zhejiang, China.

Lei GengDepartment of Surgery, Division of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University Zhejiang, China.

Shusen ZhengDepartment of Surgery, Division of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University Zhejiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the potent nucleos (t) ide analogues developed, necessity of life-long combined prophylaxis against hepatitis B virus (HBV) recurrence after HBV-related liver transplantation has been challenged. But complete withdrawal of HBV prophylaxis has not been previously observed in patients at high recurrence risk who showed active HBV replication before transplant. Herein, we describe a patient with positive HBeAg and HBV-DNA at the time of liver transplantation, who experienced complete HBV prophylaxis withdrawal after 3 years' application of hepatitis B immunoglobulin (HBIG) and entecavir, and showed no HBV recurrence during a long term of follow-up.

Indexed as

entecavirhepatitis B immunoglobulinHepatitis B virusliver transplantationprophylaxisrecurrencewithdrawal

Identifiers

PMID26221402

PMCPMC4509347

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.